Erasca, Inc.
ERASHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Erasca, Inc. focuses on Biotechnology services and products. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. With a market capitalization of $5.03B, it sits in mid-cap territory. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Market Cap
$5.03B
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-23.09
EPS (TTM)
$-0.95
EPS (Fwd)
$-0.62
ROE
-78.3%
ROA
-21.4%
Cash
$268.7M
Total Debt
$44.7M
Free CF
-$210.5M
52W Change
502.1%
Annual Financials
Cash vs Debt
Where ERAS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ERAS finished 13.47% below its 150-day moving average ($15.74) and 6.65% below its 200-day moving average ($14.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ERAS overbought or oversold?
At the October 20, 2026 close, ERAS's RSI(14) was 45.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $268.7M in cash and $44.7M in debt, ERAS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$210.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -78.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.62 suggests ERAS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ERAS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.